Literature DB >> 35074472

Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?

Yu Jun Wong1, Mindie H Nguyen2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35074472     DOI: 10.1016/j.jhep.2021.12.037

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   30.083


× No keyword cloud information.
  1 in total

1.  Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.

Authors:  Y J Wong; R Kumar; R Kumar; J Tan; C H Liu; Vw-K Hui; S S Tan; J H Kao; Gl-H Wong; P H Thurairajah
Journal:  J Gastroenterol Hepatol       Date:  2022-06-30       Impact factor: 4.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.